CSF-1R

CSF1R-IN-15 is a selective inhibitor of the colony-stimulating factor-1 receptor (CSF1R), a membrane-bound tyrosine kinase primarily expressed in macrophages. This compound disrupts CSF1R signaling, which is essential for macrophage differentiation, proliferation, and survival, by targeting its interaction with colony-stimulating factor-1 (CSF-1) and interleukin-34. CSF1R-IN-15 is valuable for research applications focused on macrophage biology and associated pathologies, including cancer, inflammation, and autoimmune diseases.

Leustroducsin B is identified as a colony-stimulating factor (CSF) inducer, primarily targeting bone marrow stromal cells. It effectively stimulates the production of CSF, which plays a critical role in hematopoiesis and immune responses. This compound is valuable for research applications focusing on hematopoietic cell differentiation and the modulation of the bone marrow microenvironment.

Leustroducsin A is a colony-stimulating factor (CSF) inducer that stimulates the production of CSF from bone marrow stromal cells. This compound is essential for research applications focused on hematopoiesis and immune response modulation. Its activity makes it a valuable tool for studying the regulation of blood cell production and potential therapeutic interventions in hematologic disorders.

Leustroducsin C is a colony-stimulating factor (CSF) inducer that stimulates the production of CSF from bone marrow stromal cells. This compound plays a critical role in hematopoiesis by enhancing the proliferation and differentiation of blood cell lineages, making it useful for research applications in immunology and regenerative medicine. Its ability to modulate the bone marrow microenvironment can be leveraged for studies on cellular interactions and therapeutic responses in various hematological conditions.

Vimseltinib is a selective dual inhibitor of c-FMS (CSF-IR) and c-Kit, demonstrating IC50 values of less than 0.01 μM and 0.1-1 μM, respectively. This compound exhibits robust biological activity, making it a valuable tool for investigating signaling pathways involved in hematopoiesis and various pathologies such as cancer and inflammatory diseases. The oral bioavailability of Vimseltinib enhances its potential for in vivo studies and therapeutic applications.

Pimicotinib is a selective and orally active inhibitor of the Colony Stimulating Factor 1 Receptor (CSF1R), with an IC50 value of 19.48 nM as determined by the inhibition of ADP production. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research applications aimed at understanding tumor microenvironment interactions and immune modulation. Researchers can utilize Pimicotinib to explore CSF1R-mediated signaling in cancer biology and potential therapeutic strategies.

Pimicotinib hydrochloride is a selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R), demonstrating an IC50 value of 19.48 nM in inhibiting ADP production. This compound exhibits notable anti-tumor activity, making it a valuable tool for research in cancer biology and immunotherapy. Its specificity for CSF1R provides insights into the modulation of macrophage activity in the tumor microenvironment.